BMO Capital Markets Issues Positive Forecast for Aveanna Healthcare (NASDAQ:AVAH) Stock Price

Aveanna Healthcare (NASDAQ:AVAH) had its price objective increased by BMO Capital Markets from $10.00 to $14.00 in a report issued on Friday,Benzinga reports. They currently have an outperform rating on the stock.

Several other research analysts have also issued reports on the stock. Stephens raised shares of Aveanna Healthcare from an “equal weight” rating to an “overweight” rating and increased their price target for the stock from $10.00 to $11.00 in a research report on Friday, May 15th. Truist Financial increased their target price on Aveanna Healthcare from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, July 14th. Royal Bank Of Canada raised Aveanna Healthcare from a “sector perform” rating to an “outperform” rating and set a $10.00 price target on the stock in a research note on Wednesday, June 3rd. Barclays upped their price target on Aveanna Healthcare from $9.00 to $9.50 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Aveanna Healthcare in a research note on Thursday, July 2nd. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and five have assigned a Hold rating to the stock. According to data from MarketBeat.com, Aveanna Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.78.

Aveanna Healthcare Stock Performance

NASDAQ:AVAH opened at $12.32 on Friday. The firm’s fifty day simple moving average is $8.97 and its 200 day simple moving average is $7.76. Aveanna Healthcare has a 1 year low of $5.93 and a 1 year high of $12.52. The firm has a market capitalization of $2.68 billion, a PE ratio of 10.02, a PEG ratio of 1.12 and a beta of 1.90. The company has a current ratio of 1.47, a quick ratio of 1.47 and a debt-to-equity ratio of 5.35.

Aveanna Healthcare (NASDAQ:AVAH) last posted its quarterly earnings results on Thursday, August 13th. The company reported $0.22 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.17 by $0.05. Aveanna Healthcare had a net margin of 10.56% and a return on equity of 99.71%. The company had revenue of $670.48 million for the quarter, compared to analyst estimates of $638.61 million. On average, sell-side analysts anticipate that Aveanna Healthcare will post 0.68 EPS for the current year.

Insider Transactions at Aveanna Healthcare

In other news, major shareholder Robert M. Williams, Jr. sold 3,000,000 shares of the company’s stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $8.01, for a total transaction of $24,030,000.00. Following the transaction, the insider owned 190,130 shares of the company’s stock, valued at $1,522,941.30. This represents a 94.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Patrick A. Cunningham sold 125,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $7.59, for a total transaction of $948,750.00. Following the completion of the transaction, the insider directly owned 212,755 shares in the company, valued at approximately $1,614,810.45. The trade was a 37.01% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 31,305,664 shares of company stock valued at $215,555,910 over the last quarter. Corporate insiders own 5.30% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AVAH. Dynamic Technology Lab Private Ltd boosted its holdings in Aveanna Healthcare by 8.9% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 14,149 shares of the company’s stock valued at $126,000 after purchasing an additional 1,151 shares during the period. Barclays PLC increased its holdings in shares of Aveanna Healthcare by 0.8% during the third quarter. Barclays PLC now owns 179,359 shares of the company’s stock worth $1,591,000 after purchasing an additional 1,366 shares during the period. Franklin Resources Inc. raised its position in shares of Aveanna Healthcare by 4.5% in the third quarter. Franklin Resources Inc. now owns 35,630 shares of the company’s stock valued at $316,000 after buying an additional 1,528 shares in the last quarter. Intech Investment Management LLC raised its position in shares of Aveanna Healthcare by 9.8% in the fourth quarter. Intech Investment Management LLC now owns 19,483 shares of the company’s stock valued at $159,000 after buying an additional 1,739 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd boosted its stake in shares of Aveanna Healthcare by 252.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 3,351 shares of the company’s stock valued at $27,000 after buying an additional 2,400 shares during the period. Institutional investors own 87.96% of the company’s stock.

Trending Headlines about Aveanna Healthcare

Here are the key news stories impacting Aveanna Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations. Revenue increased 13.7% year over year to $670.5 million, while net income rose to $40.3 million from $27.0 million. Adjusted EBITDA reached $95.4 million, up 8.0%, and adjusted EPS of $0.22 topped analyst estimates of $0.19. Aveanna Healthcare Second Quarter Financial Results and Revised 2026 Guidance
• Positive Sentiment: Management raised full-year guidance. Aveanna now expects 2026 revenue above $2.68 billion, compared with its previous $2.63 billion-$2.65 billion range, and adjusted EBITDA above $365 million, up from $338 million-$342 million. The company cited reimbursement improvements, preferred-payer relationships and continued demand for complex home care. AVAH Q2 Earnings Call Highlights Higher Growth Targets
• Positive Sentiment: Analysts lifted their price targets. BMO Capital Markets raised its target from $10 to $14 and maintained an “outperform” rating. UBS raised its target from $8 to $13, although it retained a “neutral” rating. The revisions signal improved earnings expectations and support the stock’s recent strength. Benzinga analyst price target updates
• Neutral Sentiment: Growth is concentrated in Private Duty Services, which generates roughly 83% of revenue. Rapid revenue expansion is offsetting pressure on gross margins across business segments, making margin trends an important focus for investors. Aveanna Healthcare Q2 Earnings Report

Aveanna Healthcare Company Profile

Aveanna Healthcare, Inc (NASDAQ: AVAH) is a national provider of in-home health care services, specializing in pediatric skilled nursing, therapy, and related support for medically complex and chronically ill children. The company delivers a range of clinical and therapeutic solutions designed to enable patients to receive care in the comfort of their own homes, reducing the need for hospital stays and long-term institutional care. Aveanna’s offerings include registered nursing, physical, occupational and speech therapy, behavioral health counseling, and durable medical equipment coordination.

In addition to pediatric home health services, Aveanna operates adult home health and personal care support programs, assisting elderly and disabled adults with daily living activities, medication management, and rehabilitation therapies.